In this double-blind study, 557 patients with lower respiratory tract infection were randomly assigned to receive amoxicillin/clavulanate orally either every 12 hours (875/125 mg) or every 8 hours (500/125 mg) for 7 -15 days. For the 455 patients evaluable for clinical efficacy at the end of therapy, clinical success was similar in the two groups: 93% and 94% in the 12-hour and 8-hour groups, respectively (P = .42). Bacteriologic success at the end of therapy was also comparable: 97% and 91% in the 12-hour and 8-hour groups, respectively (P = .86). The occurrence of adverse events related to treatment was similar for the two groups, but fewer patients in the 12-hour group reported moderate or severe diarrhea. Amoxicillin/clavulanate (875/125 mg) given every 12 hours is as effective and safe as every-8-hours administration of the combination (500/125 mg) for the treatment of lower respiratory tract infection.
Bacterial pneumonia and acute exacerbation of chronic bronchitis remain among the most common infections treated in the community. In the United States up to 3.3 million people develop community-acquired pneumonia each year [1] , and 50% to 90% are treated as outpatients [2] . Because of the relatively high frequency of individuals whose host defenses are compromised by age or coexistent disease, along with increasing bacterial resistance, careful selection of antimicrobial therapy is warranted.
The microbiology of community-acquired lower respiratory tract infection is changing with the emergence of resistant pathogens. This is partially attributable to changing characteristics of the general population [3, 4] . There are now greater numbers of people over age 65 years and of ambulatory patients with compromised immune function. New lower respiratory tract pathogens have emerged (such as Legionella species), and f3-lactamase-producing organisms (such as Haemophilus influenzae and Moraxella catarrhalis) are increasingly common. In addition, antibiotics tend to be used early in infectious episodes, leading to a high proportion of patients with unidentifiable pathogens.
Amoxicillin/clavulanate (Augmentin; SmithKline Beecham Pharmaceuticals, Philadelphia) is a combination product containing the semisynthetic penicillin amoxicillin and the 0-lactamase inhibitor clavulanate potassium. The established oraldose regimen for lower respiratory tract infections in adults is 500/125 mg (amoxicillin/clavulanate equivalent) given every 8 hours [5] .
In recognition of the fact that compliance is a major factor in the outcome of outpatient treatment of many infections, it is necessary to determine the most convenient dose regimen that is effective. The objective of this study was to compare the safety and efficacy of amoxicillin/clavulanate given every 12 hours (875/125 mg) to that of the combination given every 8 hours (500/125 mg) for the treatment of lower respiratory tract infections (community-acquired pneumonia and acute bacterial exacerbation of chronic bronchitis).
Methods
Study design. This was a multinational, multicentered study with 87 participating centers in the United States, Republic of Ireland, Canada, Australia, United Kingdom, Italy, Germany, Belgium, The Netherlands, Switzerland, and South Africa. Treatment was randomized and administered in a doubleblinded, double-dummy manner to two parallel treatment groups.
Patients. Inpatients or outpatients at least 18 years of age presenting with a community-acquired lower respiratory tract infection who could be treated with an oral antimicrobial were enrolled. We ensured that -50% of the patients had community-acquired pneumonia and -50% had acute exacerbation of chronic bronchitis.
Patients with community-acquired pneumonia were required to have clinical symptoms (e.g., chest pain, shortness of breath) and features suggestive of community-acquired pneumonia (e.g., fever, crackles on auscultation, bronchial breathing, dullness on percussion), cough productive of sputum, and infiltrates evident on a chest roentgenogram. Patients with acute exacerbation of chronic bronchitis were required to have a history of a cough productive of sputum on most days of the week for 3 months in each of the 2 preceding years, with an increase in quantity and/or purulence of sputum in the 48 hours before enrollment.
Patients included in the assessment of bacteriologic response were required to have an organism identified from a sputum sample collected within 2 days prior to the start of treatment. The pretreatment gram stain must have contained >25 polymorphonuclear leukocytes and < 10 epithelial cells per lowpower field. Identification of organisms was confirmed by a central study laboratory.
Antimicrobial treatment. Patients were randomly assigned to receive either oral amoxicillin/clavulanate every 12 hours (875/125 mg) plus an oral placebo (identical in appearance to the active treatment) every 8 hours or amoxicillin/clavulanate every 8 hours (500/125 mg) plus an oral placebo every 12 hours. Each regimen was administered for 7-15 days. Use of additional antimicrobials or probenecid was not permitted.
At the end of treatment, compliance was assessed to ensure that patients had received a minimum of 80% and a maximum of 120% of the prescribed medication doses.
Evaluations. Patients were evaluated for clinical and bacteriologic efficacy of treatment 48-96 hours after its initiation and then 2-4 days after its completion. In addition, assessment was performed by telephone 5-9 days after the start of treatment. Patients returned for clinical and bacteriologic evaluation 2-4 weeks after the end of treatment.
Clinical response (cure, improvement, failure, or inevaluable because of poor compliance or extenuating circumstances) was determined 2-4 days after completion of treatment. Cure was defined as complete resolution of signs and symptoms of infection, with no additional antimicrobial therapy required. Improvement was defined as incomplete resolution of the signs and symptoms of infection, with no additional antimicrobial therapy required. Failure was defined as no diminishment of the signs and symptoms of infection and/or the need for additional antimicrobial therapy. Cure and improvement were judged to be evidence of clinical success.
Sputum samples were collected for gram stain, culture, and susceptibility testing within 2 days prior to the start of treatment and then during therapy, at the end of therapy, and 2-4 weeks after treatment if the sputum was available. Serological tests were not routinely performed to identify atypical pathogens.
Bacteriologic response was determined by presence or absence of an organism 2-4 days following completion of treatment and was assessed as proven eradication (elimination of the pathogen documented by culture); presumed eradication (symptomatic response was cure or improvement and a culture was not clinically indicated); colonization (an organism appeared after treatment that did not contribute to the symptoms and signs of infection); superinfection (sputum culture showed a significant number of colonies of an organism that was different from pretreatment pathogens, that contributed to the symptoms and signs of the infection, and that required additional antimicrobial therapy); failure (noneradication of the initial pathogen); or inevaluable. Proven eradication, presumed eradication, and colonization were judged to be evidence of bacteriologic success.
The safety of the regimen was determined for all randomized patients by interview at each visit. Clinical chemistry and hematology screening tests were performed at the start of treatment and then, if clinically indicated, at the end of treatment and 2-4 weeks after completion of treatment.
Data analysis. The study was designed to enroll at least 150 evaluable patients per treatment regimen (300 patients total) to determine with 80% power (/3 = 0.20) that the lower confidence limit of the two-sided 95% confidence interval (a = 0.05) of the difference in the clinical success rates between the two treatment groups was not below -10%, with the assumption that the clinical response rate in the two groups was 90%.
Continuous data (age and duration of therapy) were analyzed by Student's t-test, while categorical data were analyzed with the x2 test. The difference in the success rates between treatment groups was assessed by analyzing a linear model with effects due to center and treatment (Statistical Analysis System, version 6.07; SAS Institute, Cary, NC). The equivalence of the two treatment groups was also assessed by determining the two-tailed 95% confidence interval of the difference in the proportions of patients with clinical and bacteriologic success. The treatment groups were considered equally effective if the lower 95% confidence limit was not below -10%.
Results
Patients. Five hundred and fifty-seven patients were randomized to receive study medication: 273 received amoxicillin/ clavulanate every 12 hours, and 284 received it every 8 hours. A total of 472 patients (85%) were evaluated at all four visits, and 455 (80%) were considered evaluable for clinical efficacy at the end of therapy. No significant differences were detected (P > .05) with respect to any of the baseline characteristics of patients (table 1) .
One hundred and two patients were excluded from the perprotocol evaluation of clinical efficacy at the end of therapy because of protocol violations (17% of the 12-hour group and 20% of the 8-hour group). Two hundred and thirty-seven patients (52%) had community-acquired pneumonia and 218 (48%) had acute exacerbation of chronic bronchitis. Compliance with the antibiotic regimen (^, 80% and 120% of doses taken) was similar for the 12-hour and 8-hour groups (96% and 94%, respectively; P = .22). Clinical response. Clinical response at the end of therapy was similar for the two treatment groups, with success rates of 93% and 94% in the 12-hour and 8-hour groups, respectively (P = .42; 95% CI for the difference was -5.3% -3.5%) (table 2). Clinical response was similar between the groups when community-acquired pneumonia and acute exacerbation of chronic bronchitis were considered separately (table 2). The 95% confidence intervals for the differences between regimens were -7.1% -4.0% for community-acquired pneumonia and -7.2%-6.7% for acute exacerbation of chronic bronchitis.
Clinical success was maintained at the time of the follow-up visit for 89% (193 of 216 patients) and 86% (185 of 215 patients) of the clinical successes at the end of treatment (P = .30) in the 12-hour and 8-hour groups, respectively. Recurrence of infection was observed in 8 patients (3.7%) and 17 patients (7.9%) in the 12-hour group and 8-hour group, respectively (P > 0.05). (8) 15 (7) 13 (6) NOTE. AECB = acute exacerbation of chronic bronchitis. The reason for the difference in the recurrence rates could not be ascertained. Recurrence was more frequent in the 8-hour group with acute exacerbation of chronic bronchitis (12.3% of patients), but differences between subgroups were not tested since these subgroup comparisons were not part of the study design.
Bacteriologic response. One hundred and thirty-nine organisms were reported for the 122 patients (59 in the 12-hour group and 63 in the 8-hour group) who were evaluable for bacteriologic efficacy. Most patients (108 of 122) had one organism isolated at presentation. The pattern of organisms isolated was similar for the two treatment groups ( Bacteriologic success (proven eradication, presumed eradication, or colonization) was similar in the two groups: 97% with the every-12-hours regimen and 91% with the every-8-hours regimen (P = .86; 95% CI for the difference, -2.5%-14.7%). Colonization was observed in five patients in the every-12-hours group and no patients in the every-8-hours group (this difference was not tested since it was a subgroup analysis that was not included in the protocol design). The responses were similar when patients with pneumonia and those with acute exacerbation of chronic bronchitis were considered separately. At the follow-up visit, bacteriologic success was maintained in 95% and 87% of patients in the 12-hour and 8-hour groups, respectively
Adverse events. One hundred and thirty-two of 557 patients (24%) reported 179 adverse events related or possibly related to the study medication (P = .39 between groups). The most common adverse event was diarrhea (11% of patients). Most of the diarrhea was mild (defined as easily tolerated by the patient, causing minimal discomfort, and not interfering with everyday activities).
Of all patients who reported moderate or severe diarrhea (moderate diarrhea was defined as sufficiently discomforting to interfere with normal everyday activities, while severe diarrhea was defined as incapacitating enough to prevent everyday activities), 50% fewer were in the 12-hour group (2.9%) than in the 8-hour group (4.9%) (P = .28). Thirty-eight patients reported 58 adverse events that led to withdrawal from the study (5.9% of the 12-hour group and 7.7% of the 8-hour group; P = .38). Gastrointestinal disturbances were the most common adverse events leading to withdrawal.
Intent-to-treat analysis. The two regimens were similar when assessed by intent-to-treat analysis of 557 patients. Clinical success at the end of therapy was achieved in 230 of 273 patients (84%) who received treatment every 12 hours and in 236 of 284 (83%) who received it every 8 hours (P = .71; 95% CI for the difference, -5.0-7.3).
Discussion
A major determinant of the success of an antimicrobial regimen in an outpatient setting is compliance, which is encouraged when a regimen is simplified to less-frequent daily dosing. Amoxicillin/clavulanate has normally been administered as a regimen of 500/125 mg (amoxicillin/clavulanate) every 8 hours for adults. In this regimen, the combination is as effective for treatment of lower respiratory tract infections as other agents such as loracarbef [6, 7] , cefuroxime [8] , and azithromycin [9, 10] .
The pharmacodynamic properties of amoxicillin/clavulanate supported consideration of every-12-hours dosing. Bacterial killing by 0-lactam antimicrobials is related to the duration of time the plasma concentration of the 0-lactam antimicrobial remains above the MIC [11] . A study of healthy volunteers demonstrated that amoxicillin/clavulanate given at a dosage of 875/125 mg every 12 hours resulted in a time above the MIC comparable to that of a dosage of 500/125 mg given every 8 hours [12] .
Within the anticipated range of MICs for organisms causing lower respiratory tract infection, the time above MIC between the two regimens would be comparable. Although compliance may be influenced by every-12-hours dosing, it is unlikely that the every-12-hours regimen will increase antimicrobial activity or the time above the MIC.
This trial documents the effectiveness of an every-12-hours regimen of amoxicillin/clavulanate (875/125 mg) in direct comparison with the standard every-8-hours regimen (500/125 mg) in patients with community-acquired pneumonia or acute exacerbation of chronic bronchitis, including patients infected with fi-lactamase-producing pathogens. The numbers of enrolled patients in each of the two disease categories may not have been sufficient to detect differences between treatment groups in each category.
As with most recent reports of community-acquired lower respiratory tract infections, the majority of pathogens isolated were organisms other than S. pneumoniae. M catarrhalis accounted for 19% of isolates, and 81% of these were /3-lactamase-positive, while H. influenzae accounted for 22% of isolates, and 13% of those were /3-lactamase-positive.
A major difficulty in treating community-acquired pneumonia is that pathogens in -50% of patients cannot be identified [3, 13] , and therapy must be initiated prior to identification even when this is possible. Antimicrobials effective against potentially resistant pathogens must therefore be used for empirical treatment.
The most common pathogens identified in studies of outpatients with community-acquired pneumonia were S. pneumoniae and H. influenzae; S. aureus, gram-negative bacilli, M. pneumoniae, Legionella species, and Chlamydia species are identified with varying frequency [14] . In studies of acute exacerbation of chronic bronchitis, M catarrhalis has gained prominence, particularly in the elderly and in patients with chronic lung diseases [15] ; this pathogen is usually (3-lactamase-producing, as are up to 40% of strains of H. influenzae [16] .
In conclusion, amoxicillin/clavulanate (875/125 mg) given every 12 hours is at least as effective and as safe as that given every 8 hours (500/125 mg) for the treatment of community-acquired lower respiratory tract infection. Reduced frequency of administration with the every-12-hours regimen should improve compliance with treatment as well as decrease the incidence of moderate to severe diarrhea. The per-day cost of the 12-hour regimen is comparable to that of the 8-hour regimen.
